摘要
目的:探讨雷珠单抗对新生血管性青光眼(Neovascular glaucoma,NVG)患者眼动脉血流动力学、房水血管活性物质和炎性因子表达水平的影响。方法:选取我院眼科2021年1月至2022年6月期间收治的拟行玻璃体切除术的NVG患者86例作为研究对象,随机分为两组(每组43人)。对照组给予玻璃体切除术治疗,观察组在对照组基础上给予玻璃体腔注射雷珠单抗治疗,观察两组患者眼压水平,眼动脉血流动力学情况,房水血管活性物质和炎性因子表达水平以及不良反应发生情况。结果:两组治疗后1 w、治疗后1 m、治疗后3 m眼压均较治疗前降低,且观察组的眼压均较对照组低(P<0.05);治疗后两组眼血流阻力系数(Resistance index,RI)均较治疗前下降,且观察组低于对照组(P<0.05);两组眼收缩期峰值流速(Peak systolic velocity,PSV)、舒张末期流速(End diastolic velocity,EDV)均较治疗前升高,且观察组高于对照组(P<0.05);治疗后两组患者房水内血管内皮生长因子(Vascular endothelial growth factor,VEGF)、白细胞介素-6(Interleukin-6,IL-6)水平均低于治疗前,且观察组较对照组低(P<0.05);两组不良反应发生率对比差异无统计学意义。结论:玻璃体腔注射雷珠单抗用于治疗NVG能够降低眼压,改善眼部动脉血流情况,抑制房水中的VEGF和IL-6表达,不增加不良发应。
Objective:To investigate the effect of rizumab on the the ocular artery blood hemodynamics,levels of vasoactive substances and inflammatory factors in patients with neovascular glaucoma(NVG).Methods:86 cases of NVG patients undergoing vitrectomy admitted to ophthalmology of our hospital from January 2021 to June 2022 were selected as study subjects and randomly divided into two groups(43 patients in each group).The control group was treated with vitrectomy,and the observation group received intravitreal ranizumab based on the control group.The intraocular pressure(IOP)level,ocular artery blood hemodynamics,levels of aqueous vasoactive substances and inflammatory factors,and adverse reactions were observed in two groups.Results:The IOP decreased one week after treatment,1 month after treatment and 3 months after treatment,and the IOP of the observation group was lower than that of the control group(P<0.05).After treatment,the Vascular resistance index(RI)after treatment were all decreased,And RI in the observation group was lower than that in the control group(P<0.05);Peak systolic flow velocity(PSV)and end-diastolic velocity(EDV)in both eye groups were all elevated,And they in the observation group were higher than those in the control group(P<0.05);levels of vascular endothelial growth factor(VEGF),interleukin-6(IL-6)were all lower,Moreover,they in the observation group was lower than those in the control group(P<0.05);There was no significant difference in the incidence of adverse effects between the two groups.Conclusion:Intravitreal injection of ranizumab to treat NVG can reduce IOP,improve ocular artery flow and inhibit the levels of VEGF and IL-6 in aqueous humor,without increasing adverse stress.
作者
袁思佳
张相冉
王延武
Yuan Si-jia;Zhang Xiang-ran;Wang Yan-wu(Department of Ophthalmology,Jinshui General Hospital of Zhengzhou City,Zhengzhou 450000,China;Department of Ophthalmology,Puyang People's Hospital,Puyang 457000,Henan,China;Ophthalmology Department,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《四川生理科学杂志》
2024年第2期299-301,390,共4页
Sichuan Journal of Physiological Sciences
